The results showed that the high-risk group showed a lower sensitivity to BI2536 (PLK1 inhibitor) and SB-505124 (TGFβR inhibitor), whereas they were sensitive to several other drugs such as AZD2014 (mTOR inhibitor), pictilisib (PI3Kα/δ inhibitor), MK-2206 (Akt inhibitor), dactolisib (dual pan-class I PI3K and mTOR kinase inhibitor), afatinib (EGFR inhibitor), rapamycin (FRAP/mTOR inhibitor), and taselisib (PI3K inhibitor targets PIK3CA mutations), even though none of these is currently used in the treatment of AML (Figure 9). This evidence concerns the gene PIK3CA and acute myeloid leukemia.